New research has shown that inhibiting PP2A can contribute to the pathology of COPD, alpha-1 antitrypsin (AAT) deficiency, lung cancer, asthma, and IPF [43,44,45,46,47,48,49,50,51]. Here, PTPA is linked to alpha 1-antitrypsin deficiency.